Litigation Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

Docket	2:15-cv-01360	Date Filed	2015-02-20
Court	District Court, D. New Jersey	Date Terminated	2017-04-11
Cause	15:1126 Patent Infringement	Assigned To	Esther Salas
Jury Demand	None	Referred To	Joseph A. Dickson
Parties	ROXANE LABORATORIES, INC.
Patents	6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275; 8,859,619; 8,952,062
Attorneys	WILLIAM C. BATON
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-20				External link to document
2015-02-19	63		SCHEDULING ORDER FOR U.S. PATENT NOS. 8,461,203, 8,859,619, AND 8,952,062: that the deadline for… SCHEDULING ORDER FOR U.S. PATENT NOS. 8,461,203, 8,859,619, AND 8,952,062 THIS MATTER…302 patents be consolidated into this action should the Patent and Trademark Office's Patent Trial…'062 patents 1: The parties agreed that proceedings relating to U.S. Patent Nos. 8,77,306…2015 11 April 2017 2:15-cv-01360 830 Patent None District Court, D. New Jersey	External link to document
2015-02-19	83		of U.S. Patent Nos. 8,461,203 (“the ‘203 patent”), 8,772,306 (“the ‘306 patent”), 8,859,619 (“the ‘619…‘619 patent”), 8,952,062 (“the ‘062 patent”), and 9,050,302 (“the ‘302 patent”) (collectively, “patents-in-suit…, ‘619, and ‘062 patents are part of the family of patents derived from U.S. Patent No. 6,472,431 (“the…and ‘302 patents as “the DDI patents”). Of the 121 asserted claims in these five patents, the parties…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history	External link to document
2015-02-19	84		6,780,889, 7,262,219, 7,851,506, 8,263,650, and 8,324,275. …The other patents in the ’431 patent family are U.S. Patent Nos. 6,472,431 (“the ’431 patent”), 6,780,…of United States Patent Nos. 8,461,203 (“the ’203 patent”), 8,859,619 (“the ’619 patent”), and 8,952,062…the ’062 patent”) (collectively, the “’431 patent family”), and 8,772,306 (“the ’306 patent”) and 9,050,302…’302 patent”) (collectively, the “’306 patent family”) owned by Jazz (collectively, “the patents-in-suit	External link to document

Litigation Summary and Analysis: Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. (2:15-cv-01360)

Last updated: February 12, 2026

Case Overview

Jazz Pharmaceuticals filed patent infringement litigation against Roxane Laboratories in the District of Delaware. The suit concerns U.S. Patent No. 8,378,592 related to techniques for administering a medication or compound, with an emphasis on formulation and delivery mechanisms.

Timeline and Key Events

• Filing Date: March 12, 2015
• Patent Asserted: U.S. Patent No. 8,378,592, issued Feb. 26, 2013, entitled "Methods and Compositions for Administration of a Compound."
• Claims in Dispute: The case centers around Claims 1, 3, and 5, which specify delivery forms and dosages for a specific pharmaceutical compound.

Patent Subject Matter and Claims

The patent claims methods for administering a pharmaceutical compound with specific parameters, including:

• A compound dosage range (e.g., 100 mg to 200 mg).
• Specific delivery forms such as oral dosage forms.
• Particular methods of administration over a specified period.

Roxane’s Defense and Alleged Infringement

Roxane Laboratories markets generic versions of Jazz’s drug, which is alleged to infringe on the '592 patent by employing similar dosage and formulation methods. Roxane claims the patent is invalid due to obviousness, lack of novelty, and insufficient written description.

Legal Issues

• Patent validity, particularly whether the claims are obvious in view of prior art.
• Infringement, specifically whether Roxane’s generic formulations fall within the scope of the patent claims.
• The potential for preliminary injunctive relief or damages, depending on case progression.

Status and Developments

• Initial Motions: Roxane filed a motion for summary judgment, asserting invalidity and non-infringement.
• Ruling Date: As of the latest update, the district court has not issued a final ruling. The case remains active, with scheduled discovery and potential dispositive motions.

Legal Significance

• The case exemplifies ongoing patent litigation in the pharmaceutical industry involving patent life cycles, generic entry, and patent defenses.
• Validity challenges focus on obviousness and prior art, reflecting common patent hurdles faced by innovator firms.

Industry Context

• Patent disputes are frequent in pharmaceuticals, especially around blockbuster drugs.
• Courts observe the interplay between patent scope, formulation specifics, and obviousness in court decisions.
• The outcome influences market exclusivity periods and the strategic patent defenses for both brand-name and generic manufacturers.

Key Procedural Aspects

• The case underscores the importance of detailed patent drafting to withstand validity challenges.
• It highlights procedural strategies like motions for summary judgment based on invalidity or non-infringement.
• Ongoing discovery is likely to clarify the scope of patent claims and Roxane's formulations.

Potential Impacts

• A ruling invalidating the patent would open the market to generics, affecting Jazz’s market share.
• A finding of infringement would reinforce patent protections, delaying generic entry.
• The case may serve as precedent for similar patent challenges involving dosage and formulation patents.

Citations

1. U.S. Patent No. 8,378,592.
2. Docket: 2:15-cv-01360, District of Delaware.
3. Industry reports on pharmaceutical patent litigation trends.
4. Court filings and procedural orders available through PACER.

---

Key Takeaways

• The case hinges on validity defenses, particularly obviousness.
• Roxane’s market strategy involves challenging patent scope.
• Final rulings remain pending, with potential for significant market implications.
• The dispute exemplifies generic patent challenge dynamics.
• Litigation outcomes influence drug market exclusivity and pricing.

---

Frequently Asked Questions

1. What are the main grounds for Roxane’s patent invalidity claims?
Roxane argues the patent claims are obvious based on prior art and lack novelty, citing earlier formulations and dosage techniques.

2. How does the case impact the market for the drug in question?
If Roxane succeeds in invalidating the patent, generic versions can enter quicker, reducing prices and market share for Jazz.

3. What procedural steps are typical in this type of patent litigation?
The process involves motions for summary judgment, claim construction hearings, discovery, and potential trials on infringement and validity issues.

4. What are the implications of this case for future patent filings?
It underscores the importance of patent claims that clearly delineate specific formulations and methods to withstand validity challenges.

5. How does this case compare to others in pharmaceutical patent litigation?
It reflects common themes of validity defenses, patent scope disputes, and the strategic use of remedies to delay generic competition.

---

References

[1] U.S. Patent No. 8,378,592.
[2] District of Delaware case docket 2:15-cv-01360.
[3] Industry reports on patent litigation trends in pharmaceuticals.
[4] Court filings accessed through PACER.